DS5565 Industry 2015 Share and Size Trends and Price Forecast and Market Analysis to 2022
Hexa Reports
Market Research Reports and Insightful Company Profiles
DS5565 Industry 2015,Share and Size,Trends and
Price,Forecast and Market Analysis to 2022
Summary
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
DS-5565 is an oral, small-molecule analgesic being developed by Daiichi Sankyo for the treatment of
PDN. It is a voltage-dependent calcium channel alpha-2-delta ligand, meaning that it has a mechanism of action similar to Lyrica and gabapentin, and reduces pain through the inhibition of calcium channelassociated currents. These compounds bind to the a-2-d subunits (a-2-d-1 and a-2-d-2) of voltagedependent calcium channels, where the a-2-d-1 subunit is the main target for the analgesic effect of a-2-
Hexa Reports
Market Research Reports and Insightful Company Profiles d ligands, while the a-2-d-2 subunit is thought to
Market Research Reports and Insightful Company Profiles
DS5565 Industry 2015,Share and Size,Trends and
Price,Forecast and Market Analysis to 2022
Summary
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
DS-5565 is an oral, small-molecule analgesic being developed by Daiichi Sankyo for the treatment of
PDN. It is a voltage-dependent calcium channel alpha-2-delta ligand, meaning that it has a mechanism of action similar to Lyrica and gabapentin, and reduces pain through the inhibition of calcium channelassociated currents. These compounds bind to the a-2-d subunits (a-2-d-1 and a-2-d-2) of voltagedependent calcium channels, where the a-2-d-1 subunit is the main target for the analgesic effect of a-2-
Hexa Reports
Market Research Reports and Insightful Company Profiles d ligands, while the a-2-d-2 subunit is thought to